Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 294

Results For "ABLE"

4971 News Found

Philips Foundation and RAD-AID International embark on a multi-year cross-continental partnership
News | September 14, 2022

Philips Foundation and RAD-AID International embark on a multi-year cross-continental partnership

Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas


Takara Bio partners with BioeXsen for the distribution of CE-IVD solutions
Supply Chain | September 14, 2022

Takara Bio partners with BioeXsen for the distribution of CE-IVD solutions

The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.


Tata Memorial Centre suggests low-cost intervention for breast cancer
News | September 13, 2022

Tata Memorial Centre suggests low-cost intervention for breast cancer

If implemented across the world, it has the capability to save over 100,000 lives annually


AIIA launches 6-week long Ayurveda Day 2022 Programme
News | September 13, 2022

AIIA launches 6-week long Ayurveda Day 2022 Programme

The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.


AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


Auretics Introduces its range of ayurvedic products
News | September 13, 2022

Auretics Introduces its range of ayurvedic products

This includes Madhurodhi, HBP Care & LBP Care for sugar & BP patients


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Diagnostic Center | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Diagnostic Center | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Diagnostic Center | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Thalassemia Sickle Cell Society receives 200000th blood units
Healthcare | September 12, 2022

Thalassemia Sickle Cell Society receives 200000th blood units

Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients